Adial Pharmaceuticals Inc (ADIL)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Cary J. Claiborne
Employees:
20
1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE, VA 22902
434-422-9800

Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction.

Data derived from most recent annual or quarterly report
Market Cap 8.327 Million Shares Outstanding28.517 Million Avg 30-day Volume 105.479 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.49
Price to Revenue0.0 Debt to Equity0.3514 EBITDA-12.731 Million
Price to Book Value6.9318 Operating Margin0.0 Enterprise Value8.174 Million
Current Ratio1.649 EPS Growth0 Quick Ratio1.286
1 Yr BETA 0.6456 52-week High/Low 2.08 / 0.2 Profit Margin0.0
Operating Cash Flow Growth5.298 Altman Z-Score-31.9193 Free Cash Flow to Firm -9.972 Million
View SEC Filings from ADIL instead.

View recent insider trading info

Adial Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ADIL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADIL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-06-02 by JOHNSON BANKOLE A.
  • 4: filed on 2023-05-25 by TRULUCK JOSEPH
  • 4: filed on 2023-05-25 by STILLEY WILLIAM B. III
  • 4: filed on 2023-05-25 by SCHUYLER KEVIN
  • 4: filed on 2023-05-25 by NEWMAN JAMES W. JR.
  • 4: filed on 2023-05-25 by GOODMAN TONY
  • 4: filed on 2023-05-25 by GILLILAND ROBERTSON H.
  • 4: filed on 2023-05-25 by ANDERSON J. KERMIT
  • 4: filed on 2023-01-03 by STILLEY WILLIAM B. III
  • 4: filed on 2022-09-20 by CLAIBORNE CARY J

    • Events (8k)

  • 8-K: filed on 2023-06-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-24:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-13:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-31:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-02:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CLAIBORNE CARY J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,520,000 2023-05-23 3

    GOODMAN TONY

    • Director
    		 0 2023-05-23 2

    ANDERSON J. KERMIT

    • Director
    		 0 2023-05-23 1

    STILLEY WILLIAM B. III

    • Director
    		 1,261,779 2023-05-23 3

    TRULUCK JOSEPH CHIEF FINANCIAL OFFICER

    • Officer
    		 265,139 2023-05-23 1

    SCHUYLER KEVIN

    • Director
    		 0 2023-05-23 1

    JOHNSON BANKOLE A.

    • Director
    		 0 2023-05-23 1

    GILLILAND ROBERTSON H.

    • Director
    		 0 2023-05-23 1

    NEWMAN JAMES W. JR.

    • Director
    		 0 2023-05-23 1

    REICH JACK W

    • Director
    		 0 2020-05-19 0

    JOHNSON BANKOLE A.

    EN FIDECOMISO DE MI VIDA 11/23/2010 TRUST

    • Director
    • 10% Owner
    		 1,467,420 2018-07-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    CLAIBORNE CARY J - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-05-25 16:36:03 -0400 2023-05-23 A 300,000 a 300,000 direct

    CLAIBORNE CARY J - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-05-25 16:36:03 -0400 2023-05-23 A 420,000 a 1,520,000 direct 0.3636 5.4545 5.4545 6 -4.3636 3

    ANDERSON J. KERMIT - Director

    		2023-05-25 16:34:24 -0400 2023-05-23 A 50,000 a 50,000 direct

    GOODMAN TONY - Director

    		2023-05-25 16:41:22 -0400 2023-05-23 A 50,000 a 50,000 direct

    GILLILAND ROBERTSON H. - Director

    		2023-05-25 16:38:50 -0400 2023-05-23 A 50,000 a 50,000 direct

    NEWMAN JAMES W. JR. - Director

    		2023-05-25 16:43:30 -0400 2023-05-23 A 50,000 a 50,000 direct

    STILLEY WILLIAM B. III - Director

    		2023-05-25 16:47:59 -0400 2023-05-23 A 50,000 a 50,000 direct

    STILLEY WILLIAM B. III - Director

    		2023-05-25 16:47:59 -0400 2023-05-23 A 240,800 a 1,261,779 direct 0.3636 5.4545 5.4545 6 -4.3636 3

    SCHUYLER KEVIN - Director

    		2023-05-25 16:45:28 -0400 2023-05-23 A 50,000 a 50,000 direct

    TRULUCK JOSEPH - Officer CHIEF FINANCIAL OFFICER

    		2023-05-25 16:50:18 -0400 2023-05-23 A 125,000 a 125,000 direct

    TRULUCK JOSEPH - Officer CHIEF FINANCIAL OFFICER

    		2023-05-25 16:50:18 -0400 2023-05-23 A 157,500 a 265,139 direct 0.3636 5.4545 5.4545 6 -4.3636 3

    JOHNSON BANKOLE A. - Director

    		2023-06-02 07:52:35 -0400 2023-05-23 A 40,000 a 40,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 22:15:04 UTC -1.6365 6.7065 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 21:45:05 UTC -1.6365 6.7065 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 21:15:04 UTC -1.6365 6.7065 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 20:45:04 UTC -1.6365 6.7065 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 20:15:06 UTC -1.6365 6.7065 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 19:45:04 UTC -1.6365 6.7065 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 19:15:04 UTC -1.6365 6.7065 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 18:45:04 UTC -1.6356 6.7056 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 18:15:03 UTC -1.6356 6.7056 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 17:45:05 UTC -1.6356 6.7056 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 17:15:04 UTC -1.6356 6.7056 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 16:45:03 UTC -1.4974 6.5674 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 16:15:04 UTC -1.4974 6.5674 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 15:45:04 UTC -1.4974 6.5674 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 15:15:04 UTC -1.4974 6.5674 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 14:45:04 UTC -1.4974 6.5674 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 14:15:03 UTC -1.4974 6.5674 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 13:45:03 UTC -1.7721 6.8421 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 13:15:04 UTC -1.7721 6.8421 350000
    ADIAL PHARMACEUTICALS INC ADIL 2023-06-07 12:45:04 UTC -1.7721 6.8421 350000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ADIL -1600.0 shares, $-560.0 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments